Navigation Links
Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results

ects $2.7 million of cash interest expense and $4.2 million of non-cash interest expense. Interest expense for the three-month period ended December 31, 2011 reflects $2.7 million of cash interest expense and $1.8 million of non-cash interest expense.

Other income, net increased $4.5 million to $5.6 million for the three-month period ended December 31, 2012, from $1.1 million for the three-month period ended December 31, 2011.  This increase is primarily due to a non-cash gain of $5.1 million during the three-month period ended December 31, 2012 relating to the mark-to-market valuation adjustment of our warrant liability.

The Company will host a live conference call and webcast on March 19, 2013, at 9:00 a.m. Eastern Time to discuss these results and to answer questions.  To participate by telephone, please dial:Domestic:


253-237-1151Conference ID:

99134844The live and archived webcast can be accessed via the investor relations section of the Savient website at  A telephone replay will be available through March 25, 2013, by dialing:



404-537-3406Conference ID:

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients who do not respond to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and c

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
3. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
4. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
5. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
6. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
7. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
8. AVANIR Pharmaceuticals To participate in two conferences in March
9. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
10. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
11. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
Post Your Comments:
(Date:10/8/2015)... ... October 08, 2015 , ... Cystic fibrosis ... conductance regulator (CFTR) gene and results in dysfunction of the lungs and the ... the lungs. This mucus is very difficult to clear, blocks the airways and ...
(Date:10/7/2015)... ... October 07, 2015 , ... The Riordan-McKenna Institute ( ... seminar on the latest advances in adult stem cell therapy for orthopedic conditions ... at the Hilton Dallas/Southlake Town Square in Southlake, Texas. , RMI offers non-surgical ...
(Date:10/7/2015)... PARK, N.C. , Oct. 7, 2015  October is ... campaign, TRL has committed to donating a portion of ... liver research and hepatology practices. ... liver research in a variety of ways; whether it ... around the world, collaborating with researchers in different disease ...
(Date:10/7/2015)... ... October 07, 2015 , ... ReliantHeart, ... S. Russel Craig of Spectral Platforms, and Michael Ward of Wrenward Medical Systems ... and consulting experience. Currently he is Executive Vice President of Strategic Relationships and ...
Breaking Biology Technology:
... Cerecor Inc. , a biopharmaceutical company focused on the ... activity is in the human nervous system, announced today ... overallotment of its January 2012 Series A preferred stock ... including members of Cerecor,s Board of Directors , ...
... American researchers have shown that prospective magnetic fusion power ... used for the production of weapon-usable materials than nuclear ... The researchers, from Princeton University, found that if nuclear ... there is little risk of fissile materials being produced ...
... N.Y. Jie Lian, assistant professor in the Department ... Institute, has won a prestigious Faculty Early Career Development ... Lian will use the five-year, $500,000 award to further ... in nuclear energy systems. The CAREER Award is given ...
Cached Biology Technology:
(Date:10/8/2015)... , October 8, 2015 ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet announces that revenues for ... approximately $410,000 compared with $113,00 for the three ... 9 months ended September 30, 2015 were approximately ...
(Date:10/5/2015)... , October 5, 2015 ... update for NXT-ID, Inc. (NASDAQ: NXTD ), a ... market. --> ) releases ... (NASDAQ: NXTD ), a biometric authentication company focused ... SoundView Technology Group ( ) releases ...
(Date:9/30/2015)... YORK , Sept. 30, 2015  The global glucose ... billion for 2015. So says a new report on the ... diabetes management segment dominate the market, followed by continuous glucose ... publisher. Kalorama reports on the market for these products in its ... ...
Breaking Biology News(10 mins):
... collection of human skulls have shown that changes to ... separate evolutionary events may have actually precipitated each other. ... examined 390 skulls from the Austrian town of Hallstatt ... integrated, meaning variation in one part of the skull ...
... on the skin to reduce signs of aging and consumed ... first evidence of one of vitamin E,s normal body functions., ... in the plasma membranes that protect cells from outside forces ... researchers report in the journal Nature Communications ., Everyday ...
... opened today for the American Chemical Society,s (ACS,) 243rd National ... the New Year. The meeting will be held March 25-29, ... the San Diego Convention Center and at area hotels. ... span science,s horizons from astronomy to zoology ― the ...
Cached Biology News:
... range of next-generation features into a small-footprint ... for flexible laboratory solutions. It puts every ... dilution, dispensing, and integrations into a ... flexible as it is efficient and economical. ...
... in any standard fixed-angle microcentrifuge rotor ... g.,Spin- centrifuge tube filters consist of ... centrifuge tube. They filter by centrifugation ... sample preparation, removal of cells from ...
... Simplify the process and you reduce ... built into the CEQ 8000. Developed using ... and leadership in capillary electrophoresis technology, the ... analysis system. This system automatically fills the ...
... The CHEMICON MDR1 Shift Assay provides a convenient ... occur upon transport of MDR1 substrates. Thus, the ... to which small molecules act as transport substrates ... in the presence of MDR1 substrates, the MDR1 ...
Biology Products: